Physiological functions and pathogenic potential of uric acid: A review

Journal of Advanced Research

Volumn 8, Issue 5, 2017, Pages 487-493

  El Ridi, Rashika ^a   Tallima, Hatem ^a,b  

^a CAIRO UNIVERSITY   (Egypt)

^b The American University in Cairo   (Egypt)

Author keywords

Arachidonic acid; Gout; Metabolic syndrome; Schistosomiasis vaccine; Type 2 cytokines; Uric acid

Indexed keywords

EID: 85016779332     PISSN: 20901232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jare.2017.03.003     Document Type: Review

References (112)

1. Chaudhary, K., Malhotra, K., Sowers, J., Aroor, A., Uric Acid - key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med 3:3 (2013), 208–220.
2. Maiuolo, J., Oppedisano, F., Gratteri, S., Muscoli, C., Mollace, V., Regulation of uric acid metabolism and excretion. Int J Cardiol 213 (2016), 8–14.
3. Chang, B.S., Ancient insights into uric acid metabolism in primates. Proc Natl Acad Sci USA 111:10 (2014), 3657–3658.
4. Kratzer, J.T., Lanaspa, M.A., Murphy, M.N., Cicerchi, C., Graves, C.L., Tipton, P.A., et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci USA 111:10 (2014), 3763–3768.
5. Ames, B.N., Cathcart, R., Schwiers, E., Hochstein, P., Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 78:11 (1981), 6858–6862.
6. Becker, B.F., Towards the physiological function of uric acid. Free Radic Biol Med 14:6 (1993), 615–631 Review.
7. Glantzounis, G.K., Tsimoyiannis, E.C., Kappas, A.M., Galaris, D.A., Uric acid and oxidative stress. Curr Pharm Des 11:32 (2005), 4145–4151.
8. Sautin, Y.Y., Johnson, R.J., Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucl Acids 27:6 (2008), 608–619.
9. Shi, Y., Evans, J.E., Rock, K.L., Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:6957 (2003), 516–521.
10. Peden, D.B., Hohman, R., Brown, M.E., Mason, R.T., Berkebile, C., Fales, H.M., et al. Uric acid is a major antioxidant in human nasal airway secretions. Proc Natl Acad Sci USA 87:19 (1990), 7638–7642.
11. Peden, D.B., Swiersz, M., Ohkubo, K., Hahn, B., Emery, B., Kaliner, M.A., Nasal secretion of the ozone scavenger uric acid. Am Rev Respir Dis 148:2 (1993), 455–461.
12. Oberbach, A., Neuhaus, J., Jehmlich, N., Schlichting, N., Heinrich, M., Kullnick, Y., et al. A global proteome approach in uric acid stimulated human aortic endothelial cells revealed regulation of multiple major cellular pathways. Int J Cardiol 176:3 (2014), 746–752.
13. Sugihara, S., Hisatome, I., Kuwabara, M., Niwa, K., Maharani, N., Kato, M., et al. Depletion of uric acid due to SLC22A12 (URAT1) loss-of-function mutation causes endothelial dysfunction in hypouricemia. Circ J 79:5 (2015), 1125–1132.
14. Iso, T., Kurabayashi, M., Extremely low levels of serum uric acid are associated with endothelial dysfunction in humans. Circ J 79:5 (2015), 978–980.
15. Nery, R.A., Kahlow, B.S., Skare, T.L., Tabushi, F.I., do Amaral e Castro, A., Uric acid and tissue repair. Arq Bras Cir Dig 28:4 (2015), 290–292.
16. Kool, M., Soullié, T., van Nimwegen, M., Willart, M.A., Muskens, F., Jung, S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205:4 (2008), 869–882.
17. Kool, M., Willart, M.A., van Nimwegen, M., Bergen, I., Pouliot, P., Virchow, J.C., et al. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 34:4 (2011), 527–540.
18. Hara, K., Iijima, K., Elias, M.K., Seno, S., Tojima, I., Kobayashi, T., et al. Airway uric acid is a sensor of inhaled protease allergens and initiates type 2 immune responses in respiratory mucosa. J Immunol 192:9 (2014), 4032–4042.
19. Gold, M.J., Hiebert, P.R., Park, H.Y., Stefanowicz, D., Le, A., Starkey, M.R., et al. Mucosal production of uric acid by airway epithelial cells contributes to particulate matter-induced allergic sensitization. Mucosal Immunol 9:3 (2016), 809–820.
20. Willart, M.A., Poulliot, P., Lambrecht, B.N., Kool, M., PAMPs and DAMPs in allergy exacerbation models. Meth Mol Biol 1032 (2013), 185–204.
21. Lambrecht, B.N., Hammad, H., Allergens and the airway epithelium response: gateway to allergic sensitization. J Allergy Clin Immunol 134:3 (2014), 499–507.
22. Hammad, H., Lambrecht, B.N., Barrier epithelial cells and the control of type 2 immunity. Immunity 43:1 (2015), 29–40 Review.
23. Anthony, R.M., Rutitzky, L.I., Urban, J.F. Jr., Stadecker, M.J., Gause, W.C., Protective immune mechanisms in helminth infecton. Nat Rev Immunol 7:12 (2007), 975–987 Review.
24. El Ridi, R., Tallima, H., Vaccine-induced protection against murine schistosomiasis mansoni with larval excretory-secretory antigens and papain or type-2 cytokines. J Parasitol 99:2 (2013), 194–202.
25. El Ridi, R., Tallima, H., Selim, S., Donnelly, S., Cotton, S., Gonzales Santana, B., et al. Cysteine peptidases as schistosomiasis vaccines with inbuilt adjuvanticity. PLoS One, 9(1), 2014, e85401.
26. El Ridi, R., Tallima, H., Dalton, J.P., Donnelly, S., Induction of protective immune responses against schistosomiasis using functionally active cysteine peptidases. Front Genet, 5, 2014, 119, 10.3389/fgene.2014.00119. eCollection 2014. Review.
27. Tallima, H., Dalton, J.P., El Ridi, R., Induction of protective immune responses against Schistosomiasis haematobium in hamsters and mice using cysteine peptidase-based vaccine. Front Immunol, 6, 2015, 130, 10.3389/fimmu.2015.00130.
28. Abdel Aziz, N., Tallima, H., Hafez, E.A., El Ridi, R., Papain-based vaccination modulates Schistosoma mansoni infection-induced cytokine signals. Scand J Immunol 83:2 (2016), 128–138.
29. Kono, H., Chen, C.J., Ontiveros, F., Rock, K.L., Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest 120:6 (2010), 1939–1949.
30. Ghaemi-Oskouie, F., Shi, Y., The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep 13:2 (2011), 160–166.
31. Szabo, G., Csak, T., Inflammasomes in liver diseases. J Hepatol 57:3 (2012), 642–654 Review.
32. Wang, W., Wang, C., Ding, X.Q., Pan, Y., Gu, T.T., Wang, M.X., et al. Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br J Pharmacol 169:6 (2013), 1352–1371.
33. Zhang, X., Zhang, J.H., Chen, X.Y., Hu, Q.H., Wang, M.X., Jin, R., et al. Reactive oxygen species-induced TXNIP drives fructose-mediated hepatic inflammation and lipid accumulation through NLRP3 inflammasome activation. Antioxid Redox Signal 22:10 (2015), 848–870.
34. Choi, Y.J., Shin, H.S., Choi, H.S., Park, J.W., Jo, I., Oh, E.S., et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest 94:10 (2014), 1114–1125.
35. Araya, J., Rodrigo, R., Videla, L.A., Thielemann, L., Orellana, M., Pettinelli, P., et al. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 106:6 (2004), 635–643.
36. Spahis, S., Alvarez, F., Dubois, J., Ahmed, N., Peretti, N., Levy, E., Plasma fatty acid composition in French-Canadian children with non-alcoholic fatty liver disease: effect of n-3 PUFA supplementation. Prostaglandins Leukot Essent Fatty Acids 99 (2015), 25–34.
37. Ma, D.W., Arendt, B.M., Hillyer, L.M., Fung, S.K., McGilvray, I., Guindi, M., et al. Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects. Nutr Diabetes, 6(7), 2016, e220.
38. El Ridi, R., Aboueldahab, M., Tallima, H., Salah, M., Mahana, N., Fawzi, S., et al. In vitro and in vivo activities of arachidonic acid against Schistosoma mansoni and Schistosoma haematobium. Antimicrob Agents Chemother 54:8 (2010), 3383–3389.
39. El Ridi, R., Tallima, H., Salah, M., Aboueldahab, M., Fahmy, O.M., Al-Halbosiy, M.F., et al. Efficacy and mechanism of action of arachidonic acid in the treatment of hamsters infected with Schistosoma mansoni or Schistosoma haematobium. Int J Antimicrob Agents 39:3 (2012), 232–239.
40. Selim, S., El Sagheer, O., El Amir, A., Barakat, R., Hadley, K., Bruins, M.J., et al. Efficacy and safety of arachidonic acid for treatment of Schistosoma mansoni-infected children in Menoufiya, Egypt. Am J Trop Med Hyg 91:5 (2014), 973–981.
41. Barakat, R., Abou El-Ela, N.E., Sharaf, S., El Sagheer, O., Selim, S., Tallima, H., et al. Efficacy and safety of arachidonic acid for treatment of school-age children in Schistosoma mansoni high-endemicity regions. Am J Trop Med Hyg 92:4 (2015), 797–804.
42. El Ridi, R., Tallima, H., Migliardo, F., Biochemical and biophysical methodologies open the road for effective schistosomiasis therapy and vaccination. Biochim Biophys Acta 1861:1 Pt B (2016), 3613–3620.
43. Amaral, K.B., Silva, T.P., Malta, K.K., Carmo, L.A.S., Dias, F.F., Almeida, M.R., et al. Natural Schistosoma mansoni infection in the wild reservoir Nectomys squamipes leads to excessive lipid droplet accumulation in hepatocytes in the absence of liver functional impairment. Plos One, 11(11), 2016, e0166979.
44. Tallima H, Dvořák J, Kareem S, Abou El Dahab M, Abdel Aziz N, Dalton JP, et al. Protective immune responses against Schistosoma mansoni infection by immunization with functionally active gut-derived cysteine peptidases alone and in combination with glyceraldehyde 3-phosphate dehydrogenase. Plos Negl Trop Dis 2017;in press.
45. Hooper, D.C., Spitsin, S., Kean, R.B., Champion, J.M., Dickson, G.M., Chaudhry, I., et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 95:2 (1998), 675–680.
46. Drulović, J., Dujmović, I., Stojsavljević, N., Mesaros, S., Andjelković, S., Miljković, D., et al. Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248:2 (2001), 121–126.
47. Sotgiu, S., Pugliatti, M., Sanna, A., Sotgiu, A., Fois, M.L., Arru, G., et al. Serum uric acid and multiple sclerosis. Neurol Sci 23:4 (2002), 183–188.
48. Rentzos, M., Nikolaou, C., Anagnostouli, M., Rombos, A., Tsakanikas, K., Economou, M., et al. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 108:6 (2006), 527–531.
49. Wang, L., Hu, W., Wang, J., Qian, W., Xiao, H., Low serum uric acid levels in patients with multiple sclerosis and neuromyelitis optica: an updated meta-analysis. Mult Scler Relat Disord 9 (2016), 17–22.
50. Alvarez-Lario, B., Macarrón-Vicente, J., Is there anything good in uric acid?. QJM 104:12 (2011), 1015–1024.
51. Fang, P., Li, X., Luo, J.J., Wang, H., Yang, X.F., A double-edged sword: uric acid and neurological disorders. Brain Disord Ther, 2(2), 2013, 109.
52. Annanmaki, T., Muuronen, A., Murros, K., Low plasma uric acid level in Parkinson's disease. Mov Disord 22:8 (2007), 1133–1137.
53. De Vera, M., Rahman, M.M., Rankin, J., Kopec, J., Gao, X., Choi, H., Gout and the risk of Parkinson's disease: a cohort study. Arthritis Rheum 59:11 (2008 Nov 15), 1549–1554.
54. Schlesinger, I., Schlesinger, N., Uric acid in Parkinson's disease. Mov Disord 23:12 (2008), 1653–1657.
55. Andreadou, E., Nikolaou, C., Gournaras, F., Rentzos, M., Boufidou, F., Tsoutsou, A., et al. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg 111:9 (2009), 724–728.
56. Pan, M., Gao, H., Long, L., Xu, Y., Liu, M., Zou, J., et al. Serum uric acid in patients with Parkinson's disease and vascular parkinsonism: a cross-sectional study. Neuroimmunomodulation 20:1 (2013), 19–28.
57. Maesaka, J.K., Wolf-Klein, G., Piccione, J.M., Ma, C.M., Hypouricemia, abnormal renal tubular urate transport, and plasma natriuretic factor(s) in patients with Alzheimer's disease. J Am Geriatr Soc 41:5 (1993), 501–506.
58. Lu, N., Dubreuil, M., Zhang, Y., Neogi, T., Rai, S.K., Ascherio, A., et al. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. Ann Rheum Dis 75:3 (2016), 547–551.
59. Yousefi, M., Rahimi, H., Barikbin, B., Toossi, P., Lotfi, S., Hedayati, M., et al. Uric acid: a new antioxidant in patients with pemphigus vulgaris. Indian J Dermatol 56:3 (2011), 278–281.
60. Barikbin, B., Yousefi, M., Rahimi, H., Hedayati, M., Razavi, S.M., Lotfi, S., Antioxidant status in patients with lichen planus. Clin Exp Dermatol 36:8 (2011), 851–854.
61. Chakraborti, G., Biswas, R., Chakraborti, S., Sen, P.K., Altered serum uric acid level in lichen planus patients. Indian J Dermatol 59:6 (2014), 558–561.
62. Bakhtiari, S., Toosi, P., Samadi, S., Bakhshi, M., Assessment of uric acid level in the saliva of patients with oral lichen planus. Med Princ Pract 26:1 (2017), 57–60.
63. McCarty, D.J., Hollander, J.L., Identification of urate crystals in gouty synovial fluid. Ann Intern Med 54 (1961), 452–460.
64. Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., Tschopp, J., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:7081 (2006), 237–241.
65. Mitroulis, I., Kambas, K., Chrysanthopoulou, A., Skendros, P., Apostolidou, E., Kourtzelis, I., et al. Neutrophil extracellular trap formation is associated with IL-1β and autophagy-related signaling in gout. PLoS One, 6(12), 2011, e29318.
66. Busso, N., Ea, H.K., The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis). Reumatismo 63:4 (2012), 230–237.
67. Amaral, F.A., Costa, V.V., Tavares, L.D., Sachs, D., Coelho, F.M., Fagundes, C.T., et al. NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout. Arthritis Rheum 64:2 (2012), 474–484.
68. Mitroulis, I., Kambas, K., Ritis, K., Neutrophils, IL-1β, and gout: is there a link?. Semin Immunopathol 35:4 (2013), 501–512.
69. Martinon, F., Update on biology: uric acid and the activation of immune and inflammatory cells. Curr Rheumatol Rep 12:2 (2010), 135–141 Review.
70. Döring, A., Gieger, C., Mehta, D., Gohlke, H., Prokisch, H., Coassin, S., et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 40:4 (2008), 430–436.
71. Dalbeth, N., Merriman, T., Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout. Rheumatology (Oxford) 48:3 (2009), 222–226 Review.
72. Martinon, F., Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev 33:1 (2010), 218–232 Review.
73. Spilberg, I., Current concepts of the mechanism of acute inflammation in gouty arthritis. Arthritis Rheum 18:2 (1975), 129–134.
74. Kanevets, U., Sharma, K., Dresser, K., Shi, Y., A role of IgM antibodies in monosodium urate crystal formation and associated adjuvanticity. J Immunol 182:4 (2009), 1912–1918.
75. Busso, N., So, A., Mechanisms of inflammation in gout. Arthritis Res Ther, 12(2), 2010, 206 Review.
76. Busso, N., So, A., Microcrystals as DAMPs and their role in joint inflammation. Rheumatology (Oxford) 51:7 (2012), 1154–1160 Review.
77. Joosten, L.A., Netea, M.G., Mylona, E., Koenders, M.I., Malireddi, R.K., Oosting, M., et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 62:11 (2010), 3237–3248.
78. Joosten, L.A., Ea, H.K., Netea, M.G., Busso, N., Interleukin-1β activation during acute joint inflammation: a limited role for the NLRP3 inflammasome in vivo. Joint Bone Spine 78:2 (2011), 107–110.
79. Franchi, L., Eigenbrod, T., Muñoz-Planillo, R., Nuñez, G., The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10:3 (2009), 241–247 Review.
80. Tschopp, J., Schroder, K., NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production?. Nat Rev Immunol 10:3 (2010), 210–215.
81. Schroder, K., Zhou, R., Tschopp, J., The NLRP3 inflammasome: a sensor for metabolic danger?. Science 327:5963 (2010), 296–300 Review.
82. Schorn, C., Frey, B., Lauber, K., Janko, C., Strysio, M., Keppeler, H., et al. Sodium overload and water influx activate the NALP3 inflammasome. J Biol Chem 286:1 (2011), 35–41.
83. Broz, P., Dixit, V.M., Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol 16:7 (2016), 407–420.
84. Desaulniers, P., Marois, S., Paré, G., Popa-Nita, O., Gilbert, C., Naccache, P.H., Characterization of an activation factor released from human neutrophils after stimulation by triclinic monosodium urate crystals. J Rheumatol 33:5 (2006), 928–938.
85. Popa-Nita, O., Naccache, P.H., Crystal-induced neutrophil activation. Immunol Cell Biol 88:1 (2010), 32–40 Review.
86. Schett, G., Dayer, J.M., Manger, B., Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol 12:1 (2016), 14–24.
87. Denoble, A.E., Huffman, K.M., Stabler, T.V., Kelly, S.J., Hershfield, M.S., McDaniel, G.E., et al. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci USA 108:5 (2011), 2088–2093.
88. Bruno, C.M., Pricoco, G., Cantone, D., Elisa Marino, E., Bruno, F., Tubular handling of uric acid and factors influencing its renal excretion: a short review. EMJ Nephrol 4:1 (2016), 92–97.
89. Bobulescu, I.A., Moe, O.W., Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis 19:6 (2012), 358–371.
90. Xu, X., Hu, J., Song, N., Chen, R., Zhang, T., Ding, X., Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrol, 18(1), 2017, 27.
91. Convento, M.S., Pessoa, E., Dalboni, M.A., Borges, F.T., Schor, N., Pro-inflammatory and oxidative effects of noncrystalline uric acid in human mesangial cells: contribution to hyperuricemic glomerular damage. Urol Res 39:1 (2011), 21–27.
92. Xiao, J., Zhang, X.L., Fu, C., Han, R., Chen, W., Lu, Y., et al. Soluble uric acid increases NALP3 inflammasome and interleukin-1β expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4-mediated pathway. Int J Mol Med 35:5 (2015), 1347–1354.
93. Xiao, J., Fu, C., Zhang, X., Zhu, D., Chen, W., Lu, Y., et al. Soluble monosodium urate, but not its crystal, induces toll like receptor 4-dependent immune activation in renal mesangial cells. Mol Immunol 66:2 (2015), 310–318.
94. Kim, S.M., Lee, S.H., Kim, Y.G., Kim, S.Y., Seo, J.W., Choi, Y.W., et al. Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. Am J Physiol Renal Physiol 308:9 (2015), F993–F1003.
95. Jalal, D.I., Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review. Curr Med Res Opin 26 (2016), 1–7.
96. Hjortnaes, J., Algra, A., Olijhoek, J., Huisman, M., Jacobs, J., van der Graaf, Y., et al. Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome. J Rheumatol 34:9 (2007), 1882–1887.
97. Choi, H.K., Ford, E.S., Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120 (2007), 442–447.
98. Sánchez-Lozada, L.G., Nakagawa, T., Kang, D.H., Feig, D.I., Franco, M., Johnson, R.J., et al. Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens 15:1 (2006), 30–33.
99. Kanbay, M., Jensen, T., Solak, Y., Le, M., Roncal-Jimenez, C., Rivard, C., et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med 29 (2016), 3–8.
100. Mazzali, M., Kanbay, M., Segal, M.S., Shafiu, M., Jalal, D., Feig, D.I., et al. Uric acid and hypertension: cause or effect?. Curr Rheumatol Rep 12:2 (2010), 108–117.
101. Kanbay, M., Segal, M., Afsar, B., Kang, D.H., Rodriguez-Iturbe, B., Johnson, R.J., The role of uric acid in the pathogenesis of human cardiovascular disease. Heart 99:11 (2013), 759–766.
102. Yu, M.A., Sánchez-Lozada, L.G., Johnson, R.J., Kang, D.H., Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 28:6 (2010), 1234–1242.
103. Park, J.H., Jin, Y.M., Hwang, S., Cho, D.H., Kang, D.H., Jo, I., Uric acid attenuates nitric oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells: a mechanism for uric acid-induced cardiovascular disease development. Nitric oxide 32 (2013), 36–42.
104. Li, P., Zhang, L., Zhang, M., Zhou, C., Lin, N., Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: a mechanism for uric acid-induced endothelial dysfunction. Int J Mol Med 37:4 (2016), 989–997.
105. Dehghan, A., van Hoek, M., Sijbrands, E.J., Hofman, A., Witteman, J.C., High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 31:2 (2008), 361–362.
106. Zou, D., Ye, Y., Zou, N., Yu, J., Analysis of risk factors and their interactions in type 2 diabetes mellitus: a cross-sectional survey in Guilin, China. J Diabetes Invest, 2016 Jul 6, 10.1111/jdi.12549.
107. Sluijs, I., Holmes, M.V., van der Schouw, Y.T., Beulens, J.W., Asselbergs, F.W., Huerta, J.M., et al. A Mendelian randomizationstudy of circulating uric acid and type 2 diabetes. Diabetes 64:8 (2015), 3028–3036.
108. Lv, Q., Meng, X.F., He, F.F., Chen, S., Su, H., Xiong, J., et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One, 8(2), 2013, e56864.
109. Johnson, R.J., Merriman, T., Lanaspa, M.A., Causal or noncausal relationship of uric acid with diabetes. Diabetes 64:8 (2015), 2720–2722.
110. Liang, C.C., Lin, P.C., Lee, M.Y., Chen, S.C., Shin, S.J., Hsiao, P.J., et al. Association of serum uric acid concentration with diabetic retinopathy and albuminuria in Taiwanese patients with type 2 diabetes mellitus. Int J Mol Sci, 17(8), 2016.
111. Schwarzmeier, J.D., Marktl, W., Moser, K., Lujf, A., Fructose induced hyperuricemia. Effects of fructose on the de novo synthesis of adenine nucleotides in the liver and skeletal muscles of rats. Res Exp Med (Berl) 162:4 (1974), 341–346.
112. Johnson, R.J., Nakagawa, T., Sanchez-Lozada, L.G., Shafiu, M., Sundaram, S., Le, M., et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 62:10 (2013), 3307–3315.